AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35618953 — intervention group
Group type: EXPERIMENTAL
Intervention: Reparixin 1200 mg orally three times daily for up to 21 days
Number of subjects: 55
Study 35618953 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 55
Study 33848641 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOW program implementation
Number of subjects: 9
Study 33848641 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation-facilitation for FLOW program
Number of subjects: 9
Study 35611778 — intervention group
Group type: EXPERIMENTAL
Intervention: 10Hz rTMS
Number of subjects: 47
Study 35611778 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 47
Study 33621540 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP plasma concentrations ≤400 pg/mL
Number of subjects: 14737
Study 33621540 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP plasma concentrations 400-999 pg/mL
Number of subjects: 14737
Study 33621540 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP plasma concentrations 1000-1999 pg/mL
Number of subjects: 14737
Study 33621540 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP plasma concentrations 2000-2999 pg/mL
Number of subjects: 14737
Study 33621540 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP plasma concentrations ≥3000 pg/mL
Number of subjects: 14737
Study 33621540 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP plasma concentrations across groups
Number of subjects: 14737
Study 32917002 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise (2 to 3 times per week)
Number of subjects: 102
Study 32917002 — intervention group
Group type: COMPARATOR
Intervention: Sedentary lifestyle (not exercising regularly)
Number of subjects: 102
Study 32917002 — intervention group
Group type: COMPARATOR
Intervention: Sedentary lifestyle
Number of subjects: 102
Study 32917002 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 102
Study 32917002 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 102
Study 33217058 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridge preservation with a xenogeneic bone substitute covered with a collagen matrix (CM-group)
Number of subjects: 75
Study 33217058 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridge preservation with a xenogeneic bone substitute covered with a free palatal graft (PG-group)
Number of subjects: 75
Study 33217058 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous healing (control)
Number of subjects: 75
Study 33217058 — intervention group
Group type: EXPERIMENTAL
Intervention: CM-group vs PG-group
Number of subjects: 75
Study 32058020 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 508
Study 32058020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 508
Study 32153330 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder SMS
Number of subjects: 200
Study 32153330 — intervention group
Group type: COMPARATOR
Intervention: No reminder SMS (Control)
Number of subjects: 200
Study 34207523 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding for ≥4 months
Number of subjects: 667
Study 34207523 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate or high levels of physical activity
Number of subjects: 667
Study 34207523 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational weight gain (GWG) ≤9 kg
Number of subjects: 667
Study 34207523 — intervention group
Group type: EXPERIMENTAL
Intervention: Modifiable factor score (range 0-3)
Number of subjects: 667
Study 33048053 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based multimodal pain program
Number of subjects: 43
Study 33048053 — intervention group
Group type: COMPARATOR
Intervention: Occlusal splint therapy (Control)
Number of subjects: 43
Study 35352280 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 75 mg QD plus ritonavir 200 mg QD
Number of subjects: 9
Study 35352280 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib 150 mg QD (control arm)
Number of subjects: 9
Study 34140229 — intervention group
Group type: EXPERIMENTAL
Intervention: Euhydrated without dousing
Number of subjects: 12
Study 34140229 — intervention group
Group type: COMPARATOR
Intervention: Hypohydrated without dousing
Number of subjects: 12
Study 34140229 — intervention group
Group type: EXPERIMENTAL
Intervention: Euhydrated with dousing
Number of subjects: 12
Study 34140229 — intervention group
Group type: COMPARATOR
Intervention: Hypohydrated with dousing
Number of subjects: 12
Study 32423463 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional collaboration concept involving GPs in regional teams with on-call schedules, pre-weekend visits, joint meetings, documentation, and improved medication safety.
Number of subjects: 1600
Study 32423463 — intervention group
Group type: COMPARATOR
Intervention: Control group receives treatment as usual.
Number of subjects: 1600
Study 32423463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 1600
Study 32423463 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1600
Study 34807347 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 0.5 ug/day orally for 6 months in ND group
Number of subjects: 134
Study 34807347 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 0.5 ug/day orally for 6 months in HD group
Number of subjects: 134
Study 34807347 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 0.5 ug/day orally for 6 months in PD group
Number of subjects: 134
Study 34807347 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation) in ND group
Number of subjects: 134
Study 34807347 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation) in HD group
Number of subjects: 134
Study 34807347 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation) in PD group
Number of subjects: 134
Study 34168105 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban for 9 consecutive months
Number of subjects: 1
Study 32314521 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla-300)
Number of subjects: 867
Study 32314521 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla-100)
Number of subjects: 867
Study 36157118 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-bacterial antibody responses in CD patients
Number of subjects: 300
Study 36157118 — intervention group
Group type: COMPARATOR
Intervention: Anti-bacterial antibody responses in healthy controls
Number of subjects: 300
Study 36157118 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker panels
Number of subjects: 300
Study 36157118 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis
Number of subjects: 300
Study 36157118 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 300
Study 34437752 — intervention group
Group type: EXPERIMENTAL
Intervention: REGN1908-1909 (600 mg)
Number of subjects: 24
Study 34437752 — intervention group
Group type: EXPERIMENTAL
Intervention: REGN1908-1909 (150 mg)
Number of subjects: 24
Study 34437752 — intervention group
Group type: EXPERIMENTAL
Intervention: REGN1908-1909 (300 mg)
Number of subjects: 24
Study 34437752 — intervention group
Group type: EXPERIMENTAL
Intervention: REGN1908-1909
Number of subjects: 24
Study 34437752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 36272526 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (AC) with cisplatin+vinorelbine
Number of subjects: 234
Study 36272526 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 234
Study 34327047 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacological interventions for POTS
Number of subjects: 0
Study 34327047 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological interventions for POTS
Number of subjects: 0
Study 34327047 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line therapies for POTS
Number of subjects: 0
Study 34327047 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line therapies for POTS
Number of subjects: 0
Study 34327047 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-line therapies for POTS
Number of subjects: 0
Study 35261056 — intervention group
Group type: EXPERIMENTAL
Intervention: 39-item checklist
Number of subjects: 26
Study 35261056 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-item OSATS GRS
Number of subjects: 26
Study 33219603 — intervention group
Group type: EXPERIMENTAL
Intervention: Racial microaggressions
Number of subjects: 140
Study 33219603 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 140
Study 35722165 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganduqing granules
Number of subjects: 60
Study 35722165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 32993879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra‐lose dose imaging protocol (ULDP)
Number of subjects: 23
Study 32993879 — intervention group
Group type: COMPARATOR
Intervention: Standard low‐dose imaging protocol (LDP)
Number of subjects: 23
Study 32993879 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ULDP and LDP
Number of subjects: 23
Study 35286358 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotation every 3 minutes
Number of subjects: 51
Study 35286358 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotation every 5 minutes
Number of subjects: 51
Study 35286358 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotation every 10 minutes
Number of subjects: 51
Study 32329435 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem extended-release
Number of subjects: 103
Study 32329435 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphic measurement
Number of subjects: 103
Study 32329435 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphic activity levels
Number of subjects: 103
Study 32329435 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported seasonality
Number of subjects: 103
Study 35218300 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate antiretroviral therapy (ART) offered through trial clinics
Number of subjects: 0
Study 35218300 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard national guidelines for ART)
Number of subjects: 0
Study 35218300 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART for PLHIV aware of their status but not on ART
Number of subjects: 0
Study 32820139 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR + exercise
Number of subjects: 46
Study 32820139 — intervention group
Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 46
Study 36039949 — intervention group
Group type: EXPERIMENTAL
Intervention: Voclosporin (23.7 mg twice daily)
Number of subjects: 534
Study 36039949 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 534
Study 36039949 — intervention group
Group type: EXPERIMENTAL
Intervention: Voclosporin
Number of subjects: 534
Study 36039949 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 534
Study 33221932 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA-assisted psychotherapy (75–125 mg) in non-taper group
Number of subjects: 50
Study 33221932 — intervention group
Group type: COMPARATOR
Intervention: MDMA-assisted psychotherapy (75–125 mg) in taper group
Number of subjects: 50
Study 33221932 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA-assisted psychotherapy (75–125 mg)
Number of subjects: 50
Study 35433441 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment summary and GA-guided management recommendations
Number of subjects: 180
Study 35433441 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no summary or recommendations)
Number of subjects: 180
Study 32152513 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg condition (2 eggs/day for 6 days/week)
Number of subjects: 30
Study 32152513 — intervention group
Group type: COMPARATOR
Intervention: Non-Egg condition (energy-matched, non-egg, higher-CHO foods)
Number of subjects: 30
Study 34488652 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up with primary care provider after discharge
Number of subjects: 16
Study 34488652 — intervention group
Group type: EXPERIMENTAL
Intervention: Role of primary care provider in coordinating care
Number of subjects: 16
Study 34488652 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of follow-up visits
Number of subjects: 16
Study 34488652 — intervention group
Group type: EXPERIMENTAL
Intervention: Link between post-discharge visit and hospital readmissions
Number of subjects: 16
Study 35726101 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injections (group 2)
Number of subjects: 71
Study 35726101 — intervention group
Group type: COMPARATOR
Intervention: Blind injections (group 1)
Number of subjects: 71
Study 34618724 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced training incorporating components of the IMB model
Number of subjects: 5672
Study 34618724 — intervention group
Group type: COMPARATOR
Intervention: Control training
Number of subjects: 5672
Study 32562440 — intervention group
Group type: EXPERIMENTAL
Intervention: New Donor Educational Materials (DnEM)
Number of subjects: 165
Study 32562440 — intervention group
Group type: COMPARATOR
Intervention: Current Donor Educational Materials (DnEM)
Number of subjects: 165
Study 33726499 — intervention group
Group type: EXPERIMENTAL
Intervention: pUDK‐HGF treatment (intramuscular injection on days 0, 14, and 28)
Number of subjects: 240
Study 33726499 — intervention group
Group type: EXPERIMENTAL
Intervention: pUDK‐HGF treatment
Number of subjects: 240
Study 33726499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 36069821 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (taxane and anthracycline-based) with investigational agents
Number of subjects: 933
Study 36069821 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (taxane and anthracycline-based) without investigational agents
Number of subjects: 933
Study 33982806 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-α-2b aerosol inhalation (5,000,000 U twice daily)
Number of subjects: 1401
Study 33982806 — intervention group
Group type: COMPARATOR
Intervention: Non-IFN-α-2b group
Number of subjects: 1401
Study 33982806 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-α-2b therapy
Number of subjects: 1401
Study 33982806 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-α-2b treatment 0–2 days after symptom onset
Number of subjects: 1401
Study 33982806 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-α-2b treatment 3–5 days after symptom onset
Number of subjects: 1401
Study 33982806 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-α-2b treatment 6–8 days after symptom onset
Number of subjects: 1401
Study 33296971 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine tablets 3.5 mg/kg
Number of subjects: 1564
Study 33296971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1564
Study 35473778 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground-based walking training (30 minutes, 2 days/week for 8 weeks, plus unsupervised walking at least 1 day/week)
Number of subjects: 24
Study 35473778 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study 33091354 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion (whole blood at a target volume of 20 mL per kg)
Number of subjects: 25893
Study 33091354 — intervention group
Group type: COMPARATOR
Intervention: No blood transfusion
Number of subjects: 25893
Study 33091354 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Number of subjects: 25893
Study 35932119 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI guided goal‐directed fluid management (GDFM)
Number of subjects: 78
Study 35932119 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluid management (CFM)
Number of subjects: 78
Study 34402253 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber intervention (total dietary fiber per day before meals)
Number of subjects: 112
Study 34402253 — intervention group
Group type: COMPARATOR
Intervention: Control group (basic nutrition support)
Number of subjects: 112
Study 34402253 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber intervention
Number of subjects: 112
Study 35882086 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative practice
Number of subjects: 0
Study 35882086 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive practice
Number of subjects: 0
Study 35882086 — intervention group
Group type: COMPARATOR
Intervention: Control group (no induced cooperative or competitive conditions)
Number of subjects: 0
Study 34377726 — intervention group
Group type: EXPERIMENTAL
Intervention: Care facilitation intervention (motivation and strengths-based case management)
Number of subjects: 113
Study 34377726 — intervention group
Group type: COMPARATOR
Intervention: Control (referral to HCV evaluation and assistance with care appointments)
Number of subjects: 113
Study 34377726 — intervention group
Group type: EXPERIMENTAL
Intervention: Care facilitation intervention
Number of subjects: 113
Study 34377726 — intervention group
Group type: COMPARATOR
Intervention: Care facilitation intervention and Control
Number of subjects: 113
Study 32740950 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed guar gum (PHGG) 10 g twice daily for 14 days prior and 14 days during pelvic radiation
Number of subjects: 30
Study 32740950 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 30
Study 33052754 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel Node (SN) biopsy
Number of subjects: 307
Study 33052754 — intervention group
Group type: COMPARATOR
Intervention: Neck Dissection (ND)
Number of subjects: 307
Study 34937821 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose heparin (HH) receiving an initial heparin dose of 450 u/kg
Number of subjects: 269
Study 34937821 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin concentration monitoring (HC) with Hepcon HMS
Number of subjects: 269
Study 34937821 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving a standard heparin dose of 300 u/kg
Number of subjects: 269
Study 36239038 — intervention group
Group type: EXPERIMENTAL
Intervention: Zavegepant 10 mg
Number of subjects: 1673
Study 36239038 — intervention group
Group type: EXPERIMENTAL
Intervention: Zavegepant 20 mg
Number of subjects: 1673
Study 36239038 — intervention group
Group type: EXPERIMENTAL
Intervention: Zavegepant 5 mg
Number of subjects: 1673
Study 36239038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1673
Study 34089165 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked training (one vowel context at a time)
Number of subjects: 0
Study 34089165 — intervention group
Group type: COMPARATOR
Intervention: Interleaved training (vowel contexts were randomized)
Number of subjects: 0
Study 32061183 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day moderate-intensity training protocol (60 min@50% peak power output)
Number of subjects: 20
Study 35263502 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 42
Study 35263502 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Resistance and Aerobic Training (CT)
Number of subjects: 42
Study 35263502 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study 32684537 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month DAPT followed by clopidogrel monotherapy
Number of subjects: 2819
Study 32684537 — intervention group
Group type: COMPARATOR
Intervention: 3-month DAPT followed by aspirin monotherapy
Number of subjects: 2819
Study 35039226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary eptifibatide and vasodilators
Number of subjects: 413
Study 35039226 — intervention group
Group type: COMPARATOR
Intervention: Thrombus aspiration alone
Number of subjects: 413
Study 34056911 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable-polymer sirolimus-eluting stent
Number of subjects: 2361
Study 34056911 — intervention group
Group type: EXPERIMENTAL
Intervention: Durable-polymer everolimus-eluting stent
Number of subjects: 2361
Study 34056911 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/severe calcification
Number of subjects: 2361
Study 34056911 — intervention group
Group type: COMPARATOR
Intervention: None/mild calcification
Number of subjects: 2361
Study 32843081 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutogliptin plus filgrastim (G-CSF)
Number of subjects: 140
Study 32843081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 35348611 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 12609
Study 35348611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12609
Study 32525525 — intervention group
Group type: EXPERIMENTAL
Intervention: Late Dinner (LD, 22:00)
Number of subjects: 20
Study 32525525 — intervention group
Group type: COMPARATOR
Intervention: Routine Dinner (RD, 18:00)
Number of subjects: 20
Study 32275653 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated curtains (ITCs)
Number of subjects: 0
Study 32275653 — intervention group
Group type: COMPARATOR
Intervention: Control arm (non-ITC clusters)
Number of subjects: 0
Study 35700653 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages that described the symptoms of health effects
Number of subjects: 1300
Study 35700653 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages that included an image depicting the health effect
Number of subjects: 1300
Study 35700653 — intervention group
Group type: COMPARATOR
Intervention: Messages with a marker word or self-efficacy cue
Number of subjects: 1300
Study 33634829 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided exercises with joint mobilization
Number of subjects: 120
Study 33634829 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided exercises without joint mobilization
Number of subjects: 120
Study 33634829 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 120
Study 33183672 — intervention group
Group type: EXPERIMENTAL
Intervention: F(ab')2 antivenom therapy plus local cryotherapy
Number of subjects: 38
Study 33183672 — intervention group
Group type: COMPARATOR
Intervention: F(ab')2 antivenom therapy
Number of subjects: 38